Nasdaq

VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

AUSTIN, Texas, Dec. 5, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded $820,000 (€740,000 Euros) and Gyros Protein Technologies AB, now ...
WGN Radio

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

In an exclusive interview, Mark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of the mental ...
Becker's Hospital Review

VolitionRx taps company to test new products seeking FDA approval

Blood test maker and epigenetics company VolitionRx is appointikng medical services company Diagnostic Oncology CRO to lead U.S. clinical tests of VolitionRx’s Nu.Q product line, with the hopes of ...
Nasdaq

Volition Signs First Human Out Licensing Deal

HENDERSON, Nev., Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and ...
Business Insider

VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference

NAMUR, Belgium, Feb. 23, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced that it will attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference being ...
Wall Street Journal

Volition Capital Raises $250 Million Fund for Small-Cap Technology Deals

Volition Capital said it closed its latest fund at $250 million, through which the technology investor aims to back high-growth, founder-owned companies. Volition Capital Fund III LP is the largest ...